At the AD/PD 2026, Roche showcased new five-year data from the Phase II PASADENA trial (NCT03100149) involving prasinezumab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results